Published by Josh White on 14th June 2021
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.
URL: http://www.digitallook.com/dl/news/story/31916498/...